

Photoaffinity Cross-Linking and Unnatural Amino Acid Mutagenesis Reveal Insights into Calcitonin Gene-Related Peptide Binding to the Calcitonin Receptor-like Receptor/Receptor Activity-Modifying Protein 1 (CLR/RAMP1) Complex

John Simms,^{†,‡} Romez Uddin,[†] Thomas P. Sakmar,[§] Joseph J. Gingell,^{||} Michael L. Garelja,^{||} Debbie L. Hay,^{||} Margaret A. Brimble,^{||} Paul W. Harris,^{||} Christopher A. Reynolds,[⊥] and David R. Poyner^{*,†}

[†]Aston University, Birmingham B4 7ET, U.K.


[‡]Coventry University, Priory Street, Coventry CV1 5FB, U.K.

[§]The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States

^{||}University of Auckland, 3A Symonds Street, Auckland 1010, New Zealand

[⊥]University of Essex, Wivenhoe Park, Colchester CO4 3SQ, U.K.

ABSTRACT: Calcitonin gene-related peptide (CGRP) binds to the complex of the calcitonin receptor-like receptor (CLR) with receptor activity-modifying protein 1 (RAMP1). How CGRP interacts with the transmembrane domain (including the extracellular loops) of this family B receptor remains unclear. In this study, a photoaffinity cross-linker, *p*-azido *L*-phenylalanine (azF), was incorporated into CLR, chiefly in the second extracellular loop (ECL2) using genetic code expansion and unnatural amino acid mutagenesis. The method was optimized to ensure efficient photolysis of azF residues near the transmembrane bundle of the receptor. A CGRP analogue modified with fluorescein at position 15 was used for detection of ultraviolet-induced cross-linking. The methodology was verified by confirming the known contacts of CGRP to the extracellular domain of CLR. Within ECL2, the chief contacts were I284 on the loop itself and L291, at the top of the fifth transmembrane helix (TMS). Minor contacts were noted along the lip of ECL2 between S286 and L290 and also with M223 in TM3 and F349 in TM6. Full length molecular models of the bound receptor complex suggest that CGRP sits at the top of the TM bundle, with Thr⁶ of the peptide making contacts with L291 and H295. I284 is likely to contact Leu¹² and Ala¹³ of CGRP, and Leu¹⁶ of CGRP is at the ECL/extracellular domain boundary of CLR. The reduced potency, E_{max} and affinity of [Leu¹⁶Ala]-human α CGRP are consistent with this model. Contacts between Thr⁶ of CGRP and H295 may be particularly important for receptor activation.



Calcitonin gene-related peptide (CGRP) is an abundant sensory neuropeptide; it is known to be a very potent vasodilator and is implicated in migraines. It is part of the calcitonin superfamily of peptides that also includes adrenomedullin, adrenomedullin 2/intermedin, and amylin.^{1,2} The peptides all bind to family B/secretin-like G protein-coupled receptors, either the calcitonin receptor or the calcitonin receptor-like receptor (CLR). However, for high-affinity binding for all of these ligands apart from calcitonin, it is necessary for the receptor to form a complex with a second transmembrane protein from the receptor activity-modifying protein (RAMP) family with only three members. The CGRP receptor is formed from CLR and RAMP1, although CGRP will also bind with high affinity to the complex of the calcitonin receptor and RAMP1.¹

The binding of endogenous peptide ligands to family B GPCRs generally follows the two-domain model in which the

N-terminal tail of the peptide interacts with the transmembrane (TM) domain of the receptor whereas the C-terminal tail binds to the extracellular domain (ECD) of the receptor.³ Recently, a number of structures of full length family B GPCRs have been published, namely, for the glucagon and glucagon-like peptide 1 (GLP-1) receptors.^{4–8} The full length calcitonin receptor has been visualized by cryo-electron microscopy, but the ECD of the receptor was very flexible and so could not be resolved. The bound salmon calcitonin peptide was also poorly resolved, and its binding mode was refined by only rigid body fitting of the calcitonin receptor ECD structure [Protein Data Bank (PDB) entry SII0] and confirmed with data from mutagenesis.⁹ For the CGRP

Received: May 2, 2018

Revised: July 9, 2018

Published: July 13, 2018

receptor, a crystal structure is available showing the C-terminal tail of a CGRP analogue bound to the ECDs of CLR and RAMP1.¹⁰ Extensive mutagenesis data that have allowed the construction of models of how CGRP interacts with the TM domain of the receptor are available.^{11–15} These studies have implicated extracellular loop 2 (ECL2) of CLR as being especially important for CGRP binding.^{12–14} However, direct evidence of molecular contacts between the ligand and receptor is lacking.

Photoaffinity cross-linking has long been used to map the binding of ligands to receptors.¹⁶ Conventionally, a photoaffinity cross-linker is incorporated into the ligand; this then requires extensive peptide mapping to identify the most likely contact point on the receptor. With the use of genetic code expansion and unnatural amino acid mutagenesis,¹⁷ it is now possible to incorporate the photoaffinity cross-linker into the receptor, thereby eliminating the need for peptide mapping or sequencing to identify contact points on the receptor. This general approach, known as targeted photo-cross-linking,¹⁸ has been used to map ligand–receptor interactions in a number of GPCRs, including the neurokinin NK-1 receptor,¹⁹ ghrelin receptor,²⁰ type 1 receptor for the corticotropin releasing factor (CRF1R),^{21–23} and GLP-1 receptor.²⁴ This has not yet been extensively applied to a complex dimeric receptor, such as the CGRP receptor. In the study presented here, we have developed a modified targeted photo-cross-linking strategy to study ECL2 of CLR and have identified two major contact points for CGRP: I284 and L291.

MATERIALS AND METHODS

Materials. Human α CGRP was from Bachem (St. Helens, U.K.). CGRP analogues were synthesized as indicated below. Alpha Screen, LANCE cAMP assay kits, reagents, plates, and ¹²⁵I-labeled human iodohistidyl¹⁰- α -CGRP were purchased from PerkinElmer (Waltham, MA).

Peptide Synthesis. [Lys(5(6)-carboxyfluorescein)¹⁵]- α -CGRP, [Leu¹²]- α -CGRP, and [Leu¹⁶]- α -CGRP were synthesized by solid phase peptide synthesis using the Fmoc/^tBu method on a 0.1 mmol scale largely as described previously.²⁵ Briefly, Rink amide ChemMatrix resin (0.48 mmol/g) was elongated using a PS3 (Protein Technologies, Tucson, AZ) automated peptide synthesizer. The Fmoc group was removed with 20% piperidine in dimethylformamide (DMF) (v/v) for 2 \times 5 min, and the Fmoc amino acids were coupled for 20 min using 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxide hexafluorophosphate and *N,N*-diisopropylethylamine. A pseudoproline, Fmoc-Leu-Ser[ψ -^{Me,Me}Pro] was used at position 16/17 to increase the synthetic efficiency.²⁶ To enable incorporation of the 5(6)-carboxyfluorescein to a side chain amine, Leu¹⁵ was substituted with Lys(Dde) [Dde = 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)-ethyl]. Boc-alanine was used as the N-terminal amino acid.

Following chain assembly, on-resin removal of the Dde group on Lys¹⁵ was accomplished with 2% hydrazine hydrate in DMF (v/v) for 2 \times 3 min, and 5(6)-carboxyfluorescein was coupled with *N,N'*-diisopropylcarbodiimide/1-hydroxybenzotriazole overnight. The resin was then treated with 20% piperidine in DMF (v/v) for 4 \times 5 min to remove excess 5(6)-carboxyfluorescein.²⁷ The crude peptide was cleaved from the resin with concomitant removal of side chain protecting groups with 94% trifluoroacetic acid, 1% triisopropylsilane, 2.5% water, and 2.5% ethanedithiol (v/v/v/v) for 3 h, precipitated with cold diethyl ether, isolated by centrifugation, dissolved in

50% aqueous acetonitrile containing 0.1% trifluoroacetic acid, and lyophilized to afford 228 mg of the crude peptide. The crude fluorescently labeled α -CGRP was analyzed by liquid chromatography and mass spectrometry (calcd mass of 4165.33 Da, found mass of 4163.30 \pm 0.9 Da) and then purified by sample displacement chromatography²⁸ on a C18 Gemini (Phenomenex) column (10 mm \times 250 mm) at a flow rate of 5 mL/min at 50 °C to give 25.1 mg of pure linear (unoxidized) [Lys(5(6)-carboxyfluorescein)¹⁵]- α -CGRP.

The linear peptide (25 mg) was dissolved in 0.1 M Tris-HCl (pH 7.85) at a concentration of 1 mg/mL, and the oxidation (disulfide formation) was allowed to proceed at room temperature open to air. Monitoring by reverse phase high-performance liquid chromatography (HPLC) indicated that the reaction was complete after 5 h. The reaction mixture was acidified to pH 2, diluted with water (60 mL), and purified by semipreparative reverse phase HPLC using a C18 Gemini column (10 mm \times 250 mm) at a flow rate of 5 mL/min at 50 °C and eluted using an appropriate gradient based on the analytical HPLC profile. Fractions containing the pure peptide were identified by electrospray mass spectrometry and/or HPLC, pooled, and lyophilized to give [Lys(5(6)-carboxyfluorescein)¹⁵]- α -CGRP at >95% purity as judged by integration of the HPLC chromatogram at 210 nm (calcd mass of 4163.31 Da, found mass of 4162.20 \pm 0.5 Da).

Unnatural Amino Acid Mutagenesis and Cross-Linking Strategy. Unnatural amino acid mutagenesis was performed in HEK293T cells as described previously,^{24,29} using Amber mutant human CLR, myc-tagged RAMP1, suppressor tRNA, and azF aminoacyl tRNA synthetase but with some modifications. HEK293T cells were seeded to a density of 800000 cells per well (resulting in 70% cell confluence the next day) of a six-well plate. Twenty-four hours after being seeded, the cells were transfected with a DNA cocktail comprising 1 μ g of mutated/WT receptor, 1 μ g of suppressor tRNA, and 0.5 μ g of aminoacyl tRNA synthetase using lipofectamine (Life Technologies catalog no. 18324-012) as per the manufacturer's instructions. Four hours post-transfection, the medium was replaced with Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% (v/v) FBS and 1 mM azF, which itself was subsequently replaced after 24 h with DMEM supplemented with 20% (v/v) FBS and 0.5 mM azF. Cells were harvested after a further 24 h, and the membrane fraction was isolated by centrifugation. The membranes were incubated with the labeled peptide for 1 h at room temperature. Once the incubation was complete, the sample was split into two equal parts. One part was pipetted into a quartz cuvette and exposed to 254 nm light for 1 h (an exposure longer than that previously reported²⁴), while the other was wrapped in aluminum foil and also placed in the light source. Heat was dissipated in both samples using silicone tubing inserted into the cuvette that was flushed with ice-cold water. Cross-linking was performed in a UVP cross-linker (Analytik-Jena AG) at an energy of 100 μ J/cm,² with the sample approximately 10 cm from the light source. Both the cross-linked samples and the control samples were pelleted by centrifugation, washed using phosphate-buffered saline, and solubilized using dodecyl maltoside for 4 h. Post-solubilization, the samples were centrifuged at 30000g for 30 min, after which 150 μ L of the soluble fraction was pipetted into a well of a 96-well plate and read using a Mithras LB 940 instrument (Berthold). The cross-linked and control samples were compared to determine the degree of peptide labeling.

Tyrosine Mutagenesis. Individual amino acids in human HA-tagged CLR were mutated to tyrosine as described previously.^{11,12,14}

cAMP Production. Human HA-tagged CLR (WT or mutant) and myc-tagged RAMP1 were transfected into HEK293T or HEK293S cells, stimulated with human α -CGRP or synthetic peptides, and cAMP accumulation was measured via Alpha Screen or LANCE as previously described.^{11,13,30}

Radioligand Binding. Competition radioligand binding assays were performed on HEK293S membranes using ¹²⁵I-labeled human α -CGRP. HEK293S cells were grown in 15 cm dishes, and each dish was transfected with 30 μ g of human HA-tagged CLR and 30 μ g of myc-tagged RAMP1 using polyethylenimine (PEI) as described previously.¹³ Forty-eight hours after transfection, membranes were isolated by homogenizing cells followed by centrifugation at 100000g for 1 h at 4 °C, and membranes were resuspended and stored at -80 °C. The binding assay was performed essentially as described previously³¹ except the membranes were incubated with labeled and unlabeled peptides for 1 h at room temperature.

Data Analysis. Concentration response curves were fitted to a three-parameter logistic equation to obtain E_{max} , pEC_{50} , and basal responses. The Hill coefficient was constrained to unity. Curve fitting was performed with GraphPad Prism version 7, as described previously.¹³ For photoaffinity cross-linking, paired Student's *t* tests were used to assess if the total cross-linking for each mutant was statistically different from the nonspecific cross-linking, accepting significance at a *P* < 0.05 level.

Molecular Modeling. Homology models of the active CLR were generated using Modeler³² utilizing the recently determined cryo-electron microscope structures of the activated GLP-1 and calcitonin receptors (PDB entries 5VAI and 5UZ7, respectively).^{8,9} One thousand models combining homology-based restraints from both templates (>2 Å root-mean-square deviation between models) were generated by Modeler using the default method. The transmembrane and loop regions of the Modeler-based structures were further refined and ranked using the membrane relax module of ROSETTA.³³ The refined models were clustered, and the best model was chosen on the basis of the largest cluster with the lowest ROSETTA membrane score.

The peptide was initially *ab initio* folded using an in-house script with a disulfide bond constraining Cys² and Cys⁷ of the peptide. Regions of secondary structure³⁴ were also imposed on the *ab initio* simulation. The best scoring folded peptide was docked on the basis of the FlexPepDock module of ROSETTA; 10000 docking solutions between the peptide and receptor were generated. The FlexPepDock docked solutions were filtered in two stages. The docked solutions were initially filtered using analogous contact restraints (cutoff of 5 Å) as observed in the 4RWG crystal structure.⁹ These results were further filtered by keeping any solution in which both Ile²⁸⁴ and Leu²⁹¹ were within 5 Å of any atom of the docked CGRP ligand. The filtered results (737 docked poses) were then further refined using the membrane relax module also found in the ROSETTA suite of software. The middle structure of the largest, lowest-energy cluster was chosen for further analysis.

Replica exchange Monte Carlo simulations as implemented in Hippo³⁵ were used to explore the conformational space of the

ROSETTA-refined model. Sixteen replicas were simulated over the temperature range of 300–500 K following a Boltzmann distribution in a 30 Å implicit membrane. Other variables were kept as the default settings. The trajectory was visualized using Visual Molecular Dynamics.³⁶

RESULTS

Activity of [Lys(5(6)-carboxyfluorescein)¹⁵] Human α -CGRP (15-Fluo CGRP). To identify cross-linking to CLR, a fluorescent CGRP agonist was required. On the basis of previously published structure–activity data,³⁷ supported by molecular modeling,^{11,38} we reasoned that it should be possible to modify CGRP at position 15 while retaining agonist activity. The native Leu at this residue was replaced by Lys and derivatized with 5(6)-carboxyfluorescein. The resulting analogue was evaluated for its ability to stimulate cAMP production via the CGRP receptor. While it had reduced potency, it was a full agonist (Figure 1), suggesting that this modification did not greatly affect the functional properties of the ligand




Figure 1. cAMP production on HEK293T cells transfected with CLR and RAMP1 and exposed to CGRP or 15-Fluo CGRP for 15 min. Values are means \pm the standard error of the mean (SEM); *n* = 3 independent experiments.

Confirmation of the Cross-Linking Strategy. Preliminary experiments indicated that optimal specific cross-linking was obtained following a 1 h exposure to ultraviolet (UV) light. The availability of a crystal structure showing the binding of a modified CGRP analogue to the extracellular domain of the CGRP receptor¹⁰ provided a system for evaluating our methodology. A series of azF mutants was constructed in which residues within 5 Å of or more than 7 Å from the bound CGRP analogue were substituted. There was excellent agreement between the ability of the mutants to cross-link to CGRP and their distances from the bound CGRP analogue in the crystal structure (Figure 2).

Cross-Linking by Residues in ECL2. A scan was then performed on ECL2 of CLR and its flanking regions from H270 to Y292, excluding C282, which is involved in a conserved disulfide bond with C212 at the extracellular end of TM3. The data suggest that major points of attachment for 15-Fluo CGRP are I284 and L291, with much weaker although significant labeling in a number of other positions at the distal end of the loop (Figure 3). There was virtually no specific labeling at any position in the loop proximal to D280. It is possible that a lack of labeling might simply reflect the fact that the receptor is nonfunctional when substituted with azF. To test this, a Tyr scan of the residues mutated to azF was performed, excluding the native tyrosines at positions 277 and 278 (Figure 4). A Tyr rather than an azF scan was performed




Figure 2. Fluorescence of solubilized HEK293T cell membranes from cells transfected with RAMP1 and CLR containing azF substitutions at the indicated residues. Membranes were exposed to 15-Fluo CGRP in the presence or absence of UV light. D94, H114, W121, and N128 are all within 5 Å of bound CGRP;¹⁰ other residues are 7–10 Å away. Values are means ± SEM; *n* = 3. **P* < 0.05, and ***P* < 0.01; values of total labeling that are significantly different from the nonspecific values in the paired control samples, i.e., in the absence of UV light.




Figure 3. Fluorescence of solubilized HEK293T cell membranes from cells transfected with RAMP1 and CLR containing azF substitutions at the indicated residues. Membranes were exposed to 15-Fluo CGRP in the presence or absence of UV light. The values are the specific labeling, following subtraction of the nonspecific from total bound fluorescence. Values are means ± SEM; *n* = 3–6. **P* < 0.05; values for which total labeling is significantly different from the nonspecific values in the paired control samples, i.e., in the absence of UV light. Nonspecific labeling ranged from 2247 to 5759 AU.




Figure 4. Tyrosine scan of ECL2. Potency of human α-CGRP at stimulating cAMP production in HEK293T cells transfected with CLR (WT or mutants) and RAMP1. Values are means ± SEM; *n* = 3.

because the modified aminoacyl tRNA synthetase used to incorporate azF will also accept Tyr, albeit at lower efficiency, resulting in a mixed population of receptors potentially with

one of two different residues at the same site.²⁴ Tyr is structurally the closest natural amino acid to azF. The results showed that all the mutants assessed should still be able to interact with 15-Fluo CGRP at 100 nM, the concentration used in our cross-linking experiments, as the Tyr mutants retained a good sensitivity to CGRP.

Role of TM3 and TM6. The current cross-linking data and previous mutation studies have indicated that ECL2 and the first turn of TMS are important in forming the binding site for CGRP. We extended the use of our cross-linking method to address the role of other parts of the receptor. M223 (TM3) and F349 (TM6) were mutated to azF. These residues are likely to face into the TM bundle of CLR but are approximately two helical turns deeper into the TM bundle than L291 is (Figure 6). Thus, they provide insight into how far CGRP penetrates into the TM core of CLR. The specific cross-linking seen with both of these residues was comparable with that of S286 (Figure 5), which appears to act as a minor




Figure 5. Fluorescence of solubilized HEK293T cell membranes from cells transfected with RAMP1 and CLR containing azF substitutions at the indicated residues. Membranes were exposed to 15-Fluo CGRP in the presence or absence of UV light. Values are means ± SEM; *n* = 3. **P* < 0.05; values of total labeling significantly different from the nonspecific values in the paired control samples, i.e., in the absence of UV light.

contact in ECL2 (Figure 3), although we cannot exclude a lower cross-linking efficiency due to poor photolysis of residues deep in the TM bundle. It seems likely that M223 and F349 are at the base of the binding pocket for CGRP.

Molecular Modeling of Bound CGRP. Our modeling suggests that CGRP extends down as far as H295, in TMS. I284 is close to Leu¹² and Ala¹³ of CGRP, and L291 is adjacent to Thr⁶ of CGRP (Figure 6). Leu¹⁶ of CGRP is the most proximal residue of the bound CGRP to make potential contact with the ECLs. It is close to I284 and V198 (in ECL1) but is also in the proximity of I32 of the ECD, perhaps making contact with both ECLs and the ECD of CLR.

Activity of [Leu¹²Ala]- and [Leu¹⁶Ala]-Human α-CGRP. To further test our proposed mode of binding, we investigated the ability of [Leu¹²Ala]- and [Leu¹⁶Ala]-human α-CGRP to stimulate cAMP. Both analogues showed substantial reductions in potency and *E*_{max} with [Leu¹⁶Ala]-human α-CGRP showing the largest effects (Figure 7). This result was confirmed in a radioligand binding assay, in which [Leu¹⁶Ala]-human α-CGRP also showed a substantial reduction in affinity.




Figure 6. Molecular model of the CLR (brown ribbon)/RAMP1 (blue ribbon; TM region omitted for the sake of clarity) complex with bound CGRP (pink ribbon). (A) Detail of predicted interactions of CGRP with I284 and L291. (B) Predicted position of bound CGRP with residues on the periphery of the binding site. CLR residues shown in space-filling mode; CGRP residues colored green. The models can be viewed online using Molecule Viewer³⁹ at <https://bit.ly/2FnQAHp> (recommended browsers are Google Chrome in incognito mode or Firefox). (C) Full length structure of the CLR complex. The positions of TMS and helix 8 are highlighted to aid orientation.

DISCUSSION

We have used unnatural amino acid mutagenesis to map key residues in and adjacent to ECL2 of CLR that contribute to the binding of CGRP. The data suggest that I284 and L291 make contacts in the vicinity of Thr⁶ and Leu¹² of bound CGRP. This binding orientation is consistent with the modeled position of calcitonin in the cryo-electron microscopy structure of the calcitonin receptor.⁹

A number of the residues that we have identified in this study as contributing to the binding of CGRP have been previously identified as being important for CGRP production of cAMP, based on mutagenesis. We predicted that I284 could interact with one or more CGRP residues C-terminal to the 2–7 disulfide-bonded loop of the peptide, conventionally considered to be the mediator of receptor activation.¹³ However, using an alanine scan, we have previously found that changes to Val⁸ and Thr⁹ of CGRP can alter its efficacy.²⁵ Our current model suggests that Val⁸ is adjacent to H194 in TM2 and Thr⁹ is in the proximity of the backbone of ECL2. Our study further extends this by demonstrating that Leu¹⁶ in CGRP can influence efficacy, potentially by contacting I32 in the ECD of CLR. Furthermore, we have observed during a replica exchange Monte Carlo simulation of the bound CGRP (to investigate dynamic stability), L16 periodically interacts with V198 (ECL1) and I284 of CLR. V198 and I32 have both been shown to be important for cAMP production by CGRP.^{40,41} These observations suggest how CGRP residues




Figure 7. Comparison of the ability of [Leu¹²Ala]- and [Leu¹⁶Ala]-human α -CGRP (A) to stimulate cAMP in HEK293S cells transfected with HA-CLR and myc-RAMP1 or (B) to displace [¹²⁵I]CGRP at the CGRP receptor. Values are means \pm SEM; $n = 3$ or 4.

outside of the classic 1–7 “activation” domain of the peptide can influence efficacy; we speculate that Leu¹⁶ may be particularly important in interacting with both the ECLs and ECD of CLR. It may therefore be possible to develop truncated analogues that retain agonist activity by interacting with the upper regions of the TM bundle and ECLs, as has been done for GLP-1.⁴²

Within the 1–7 region of CGRP, our previous structure–activity work indicated that Thr⁶ was essential for agonism. In fact, this residue is absolutely conserved in all members of the calcitonin family of peptides.^{25,34} In our model, Thr⁶ of CGRP is close to not only L291 of TMS but also H295 a turn lower. Previous mutagenesis has shown that H295 is important for the activation of all CLR/RAMP complexes with both CGRP and adrenomedullin;¹¹ its equivalent is also important for agonism by calcitonin in the calcitonin receptor.⁹ Molecular dynamics simulations indicated that H295, at the top of TMS, controls interhelical contacts among TM3, TMS, TM6, and TM7 of CLR. A rotation of this residue caused helix sliding and tilting that opened the G protein binding pocket.¹¹ Residues deeper in the receptor that are important for receptor activation such as E348¹¹ would seem unlikely to be significant ligand contacts, unless they are connected by bound water molecules.

Although I284 and L291 were the main contacts revealed in this study, it is interesting to note that there were a range of minor contacts in the distal part of ECL2. The pattern here was that every other residue between I284 and L290 appeared as contacts. Interestingly, our previous mutagenesis and modeling have suggested that this forms a short stretch of β -strand, along the rim of the cavity between TM4 and TMS.¹² This secondary structure element is consistent with the labeling pattern.

In eight of 15 of the human family B GPCRs, the equivalent of I284 is glutamic or aspartic acid; in three additional receptors, it is threonine. Only in CLR, the calcitonin receptor (leucine), and the corticotrophin receptors (phenylalanine) is the corresponding residue hydrophobic. Thus, within family B GPCRs, this residue may be important in ligand specificity; it faces into the core of the receptor where it can be resolved in structures. In the calcitonin receptor, the equivalent residue is important for the binding of human and porcine but not salmon calcitonin, indicating how similar ligands can differentially interact with residues within their binding pockets.⁴³ The absence of labeling for W283 is noteworthy as this residue is highly conserved in family B GPCRs and mutation may show deleterious effects.^{44,45} Its side chain orientation is variable in the current family B GPCR structures, either facing into the core in the calcitonin and glucagon receptor structures or inserting between TM3 and TM4 in other structures.^{4,5,9,46} These data suggest that W283 does not contact the peptide, indicating it is most likely to be inserted between TM3 and TM4 (Figure 6B).

The techniques described in this paper may be applied to other receptors. While previously the method has been applied to the GLP-1 receptor,²⁴ our experience is that significant refinement is required. In the study presented here, it was necessary to illuminate the receptor for 1 h to obtain cross-linking, rather than for the 5 min used in the GLP-1 study. This difference may reflect the fact that the GLP-1 study was focused on the extracellular domain of the receptor; greater exposure times may be necessary for residues within the membrane domain. In studies of CRF1R, where transmembrane residues were also targeted, illumination was performed for 20–40 min.^{21,22} Thus, investigators should optimize labeling conditions to ensure their protocols are maximally effective. The cross-linking efficiency will also depend on the power of the UV source and the distance of the sample from the light, which are likely to vary between laboratories.

In conclusion, this study suggests that CGRP binds to a pocket formed by the ECLs of CLR, penetrating approximately two turns into the TM region. Direct contacts with residues here and in the ECLs form the basis of the agonist-induced conformational shift in CLR during receptor activation.

AUTHOR INFORMATION

Corresponding Author

*E-mail: d.r.poyner@aston.ac.uk. Telephone: +44 (0)121 204 3997.

ORCID

Debbie L. Hay: [0000-0002-9558-5122](https://orcid.org/0000-0002-9558-5122)

Margaret A. Brimble: [0000-0002-7086-4096](https://orcid.org/0000-0002-7086-4096)

David R. Poyner: [0000-0003-1590-112X](https://orcid.org/0000-0003-1590-112X)

Author Contributions

The manuscript was written through contributions of all authors. J.S., R.U., J.J.G., and M.L.G. performed experiments. T.P.S. provided constructs for photoaffinity labeling and technical advice. P.W.H. and M.A.B. synthesized peptides. J.S., C.A.R., T.P.S., D.R.P., and D.L.H. interpreted experiments and wrote the paper. All authors have given approval to the final version of the manuscript.

Funding

This work was supported by BBSRC grants to D.R.P. (BB/M007529/1) and C.A.R. (BB/M006883/1). C.A.R. is a Royal

Society Industry Fellow. D.L.H. is a James Cook Research Fellow of the Royal Society of New Zealand.

Notes

The authors declare no competing financial interest.

To access the research data supporting this publication, see <https://doi.org/10.17036/researchdata.aston.ac.uk.00000368>.

ACKNOWLEDGMENTS

The authors thank Dr. Casandra Koole and Dr. Harriet Watkins for advice. Furthermore, the authors thank Merry Wang at Autodesk for help and advice with Molecule Viewer.

ABBREVIATIONS

azF-p, azido L-phenylalanine; AM, adrenomedullin; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; CT, calcitonin; Dde, 1-(4,4-dimethyl-2,6-dioxacyclohexylidene)ethyl; DMF, dimethylformamide; ECD, extracellular domain; ECL, extracellular loop; GLP-1, glucagon-like peptide-1; GPCR, G protein-coupled receptor; RAMP, receptor activity-modifying protein; TM, transmembrane.

REFERENCES

- (1) Hay, D. L., Garejja, M. L., Poyner, D. R., and Walker, C. S. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. *Br. J. Pharmacol.* 175, 3–17.
- (2) Hay, D. L., and Walker, C. S. (2017) CGRP and its receptors. *Headache* 57, 625–636.
- (3) Hoare, S. R. (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. *Drug Discovery Today* 10, 417–427.
- (4) Zhang, H., Qiao, A., Yang, D., Yang, L., Dai, A., de Graaf, C., Reedt-Runge, S., Dharmarajan, V., Zhang, H., Han, G. W., Grant, T. D., Sierra, R. G., Weierstall, U., Nelson, G., Liu, W., Wu, Y., Ma, L., Cai, X., Lin, G., Wu, X., Geng, Z., Dong, Y., Song, G., Griffin, P. R., Lau, J., Cherezov, V., Yang, H., Hanson, M. A., Stevens, R. C., Zhao, Q., Jiang, H., Wang, M. W., and Wu, B. (2017) Structure of the full-length glucagon class B G-protein-coupled receptor. *Nature* 546, 259–264.
- (5) Jazayeri, A., Rappas, M., Brown, A. J. H., Kean, J., Errey, J. C., Robertson, N. J., Fiez-Vandal, C., Andrews, S. P., Congreve, M., Bortolato, A., Mason, J. S., Baig, A. H., Teobald, I., Dore, A. S., Weir, M., Cooke, R. M., and Marshall, F. H. (2017) Crystal structure of the GLP-1 receptor bound to a peptide agonist. *Nature* 546, 254–258.
- (6) Zhang, H., Qiao, A., Yang, L., Van Eps, N., Frederiksen, K. S., Yang, D., Dai, A., Cai, X., Zhang, H., Yi, C., Cao, C., He, L., Yang, H., Lau, J., Ernst, O. P., Hanson, M. A., Stevens, R. C., Wang, M. W., Reedt-Runge, S., Jiang, H., Zhao, Q., and Wu, B. (2018) Structure of the glucagon receptor in complex with a glucagon analogue. *Nature* 553, 106–110.
- (7) Liang, Y. L., Khoshouei, M., Glukhova, A., Furness, S. G. B., Zhao, P., Clydesdale, L., Koole, C., Truong, T. T., Thal, D. M., Lei, S., Radjainia, M., Danev, R., Baumeister, W., Wang, M. W., Miller, L. J., Christopoulos, A., Sexton, P. M., and Wootten, D. (2018) Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex. *Nature* 555, 121–125.
- (8) Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., and Skiniotis, G. (2017) Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. *Nature* 546, 248–253.
- (9) Liang, Y. L., Khoshouei, M., Radjainia, M., Zhang, Y., Glukhova, A., Tarrasch, J., Thal, D. M., Furness, S. G. B., Christopoulos, G., Coudrat, T., Danev, R., Baumeister, W., Miller, L. J., Christopoulos, A., Kobilka, B. K., Wootten, D., Skiniotis, G., and Sexton, P. M. (2017) Phase-plate cryo-EM structure of a class B GPCR-G-protein complex. *Nature* 546, 118–123.

- (10) Booe, J. M., Walker, C. S., Barwell, J., Kuteyi, G., Simms, J., Jamaluddin, M. A., Warner, M. L., Bill, R. M., Harris, P. W., Brimble, M. A., Poyner, D. R., Hay, D. L., and Pioszak, A. A. (2015) Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor. *Mol. Cell* 58, 1040–1052.
- (11) Woolley, M. J., Reynolds, C. A., Simms, J., Walker, C. S., Mobarec, J. C., Garelja, M. L., Conner, A. C., Poyner, D. R., and Hay, D. L. (2017) Receptor activity-modifying protein dependent and independent activation mechanisms in the coupling of calcitonin gene-related peptide and adrenomedullin receptors to Gs. *Biochem. Pharmacol.* 142, 96–110.
- (12) Woolley, M. J., Simms, J., Mobarec, J. C., Reynolds, C. A., Poyner, D. R., and Conner, A. C. (2017) Understanding the molecular functions of the second extracellular loop (ECL2) of the calcitonin gene-related peptide (CGRP) receptor using a comprehensive mutagenesis approach. *Mol. Cell. Endocrinol.* 454, 39–49.
- (13) Woolley, M. J., Simms, J., Uddin, S., Poyner, D. R., and Conner, A. C. (2017) Relative Antagonism of Mutants of the CGRP Receptor Extracellular Loop 2 Domain (ECL2) Using a Truncated Competitive Antagonist (CGRP8–37): Evidence for the Dual Involvement of ECL2 in the Two-Domain Binding Model. *Biochemistry* 56, 3877–3880.
- (14) Woolley, M. J., Watkins, H. A., Taddese, B., Karakullukcu, Z. G., Barwell, J., Smith, K. J., Hay, D. L., Poyner, D. R., Reynolds, C. A., and Conner, A. C. (2013) The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach. *J. R. Soc., Interface* 10, 20130589.
- (15) Vohra, S., Taddese, B., Conner, A. C., Poyner, D. R., Hay, D. L., Barwell, J., Reeves, P. J., Upton, G. J., and Reynolds, C. A. (2013) Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies, *Journal of the Royal Society. J. R. Soc., Interface* 10, 20120846.
- (16) Dong, M., and Miller, L. J. (2006) Use of photoaffinity labeling to understand the molecular basis of ligand binding to the secretin receptor. *Ann. N. Y. Acad. Sci.* 1070, 248–264.
- (17) Wang, L., Brock, A., Herberich, B., and Schultz, P. G. (2001) Expanding the genetic code of *Escherichia coli*. *Science* 292, 498–500.
- (18) Grunbeck, A., and Sakmar, T. P. (2013) Probing G protein-coupled receptor-ligand interactions with targeted photoactivatable cross-linkers. *Biochemistry* 52, 8625–8632.
- (19) Valentin-Hansen, L., Park, M., Huber, T., Grunbeck, A., Naganathan, S., Schwartz, T. W., and Sakmar, T. P. (2014) Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid. *J. Biol. Chem.* 289, 18045–18054.
- (20) Park, M., Sivertsen, B. B., Els-Heindl, S., Huber, T., Holst, B., Beck-Sickinger, A. G., Schwartz, T. W., and Sakmar, T. P. (2015) Bioorthogonal Labeling of Ghrelin Receptor to Facilitate Studies of Ligand-Dependent Conformational Dynamics. *Chem. Biol.* 22, 1431–1436.
- (21) Coin, I., Katritch, V., Sun, T., Xiang, Z., Siu, F. Y., Beyermann, M., Stevens, R. C., and Wang, L. (2013) Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR. *Cell* 155, 1258–1269.
- (22) Seidel, L., Zarzycka, B., Zaidi, S. A., Katritch, V., and Coin, I. (2017) Structural insight into the activation of a class B G-protein-coupled receptor by peptide hormones in live human cells. *eLife* 6, e27711.
- (23) Coin, I., Perrin, M. H., Vale, W. W., and Wang, L. (2011) Photo-cross-linkers incorporated into G-protein-coupled receptors in mammalian cells: a ligand comparison. *Angew Chem Int Ed Engl. Angew. Chem., Int. Ed.* 50, 8077–8081.
- (24) Koole, C., Reynolds, C. A., Mobarec, J. C., Hick, C., Sexton, P. M., and Sakmar, T. P. (2017) Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R). *J. Biol. Chem.* 292, 7131–7144.
- (25) Hay, D. L., Harris, P. W., Kowalczyk, R., Brimble, M. A., Rathbone, D. L., Barwell, J., Conner, A. C., and Poyner, D. R. (2014) Structure-activity relationships of the N-terminus of calcitonin gene-related peptide: key roles of alanine-5 and threonine-6 in receptor activation. *Br. J. Pharmacol.* 171, 415–426.
- (26) Wöhr, T., and Mutter, M. (1995) Pseudo-prolines in peptide synthesis: Direct insertion of serine and threonine derived oxazolidines in dipeptides. *Tetrahedron Lett.* 36, 3847–3848.
- (27) Fischer, R., Mader, O., Jung, G., and Brock, R. (2003) Extending the Applicability of Carboxyfluorescein in Solid-Phase Synthesis. *Bioconjugate Chem.* 14, 653–660.
- (28) Harris, P. W. R., Lee, D. J., and Brimble, M. A. (2012) A slow gradient approach for the purification of synthetic polypeptides by reversed phase high performance liquid chromatography. *J. Pept. Sci.* 18, 549–555.
- (29) Ye, S., Kohrer, C., Huber, T., Kazmi, M., Sachdev, P., Yan, E. C., Bhagat, A., RajBhandary, U. L., and Sakmar, T. P. (2008) Site-specific incorporation of keto amino acids into functional G protein-coupled receptors using unnatural amino acid mutagenesis. *J. Biol. Chem.* 283, 1525–1533.
- (30) Garelja, M. L., Walker, C. A., Siow, A., Yang, S. H., Harris, P. W. R., Brimble, M. A., Watkins, H. A., Gingell, J. J., and Hay, D. L. (2018) Receptor Activity Modifying Proteins Have Limited Effects on the Class B G Protein-Coupled Receptor Calcitonin Receptor-Like Receptor Stalk. *Biochemistry* 57, 1410–1422.
- (31) Qi, T., Christopoulos, G., Bailey, R. J., Christopoulos, A., Sexton, P. M., and Hay, D. L. (2008) Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. *Mol. Pharmacol.* 74, 1059–1071.
- (32) Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.* 234, 779–815.
- (33) Barth, P., Schonbrun, J., and Baker, D. (2007) Toward high-resolution prediction and design of transmembrane helical protein structures. *Proc. Natl. Acad. Sci. U. S. A.* 104, 15682–15687.
- (34) Watkins, H. A., Rathbone, D. L., Barwell, J., Hay, D. L., and Poyner, D. R. (2013) Structure-activity relationships for alpha-calcitonin gene-related peptide. *Br. J. Pharmacol.* 170, 1308–1322.
- (35) Ulmschneider, J. P., and Ulmschneider, M. B. (2009) Sampling efficiency in explicit and implicit membrane environments studied by peptide folding simulations. *Proteins: Struct., Funct., Genet.* 75, 586–597.
- (36) Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD - Visual Molecular Dynamics. *J. Mol. Graphics* 14, 33–38.
- (37) Howitt, S. G., Kilk, K., Wang, Y., Smith, D. M., Langel, U., and Poyner, D. R. (2003) The role of the 8–18 helix of CGRP8–37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. *Br. J. Pharmacol.* 138, 325–332.
- (38) Watkins, H. A., Chakravarthy, M., Abhayawardana, R. S., Gingell, J. J., Garelja, M., Pardamwar, M., McElhinney, J. M., Lathbridge, A., Constantine, A., Harris, P. W., Yuen, T. Y., Brimble, M. A., Barwell, J., Poyner, D. R., Woolley, M. J., Conner, A. C., Pioszak, A. A., Reynolds, C. A., and Hay, D. L. (2016) Receptor Activity-modifying Proteins 2 and 3 Generate Adrenomedullin Receptor Subtypes with Distinct Molecular Properties. *J. Biol. Chem.* 291, 11657–11675.
- (39) Balo, A. R., Wang, M., and Ernst, O. P. (2017) Accessible virtual reality of biomolecular structural models using the Autodesk Molecule Viewer. *Nat. Methods* 14, 1122–1123.
- (40) Barwell, J., Conner, A., and Poyner, D. R. (2011) Extracellular loops 1 and 3 and their associated transmembrane regions of the calcitonin receptor-like receptor are needed for CGRP receptor function. *Biochim. Biophys. Acta, Mol. Cell Res.* 1813, 1906–1916.
- (41) Barwell, J., Miller, P. S., Donnelly, D., and Poyner, D. R. (2010) Mapping interaction sites within the N-terminus of the calcitonin gene-related peptide receptor; the role of residues 23–60 of the calcitonin receptor-like receptor. *Peptides* 31, 170–176.

(42) Hoang, H. N., Song, K., Hill, T. A., Derksen, D. R., Edmonds, D. J., Kok, W. M., Limberakis, C., Liras, S., Loria, P. M., Mascitti, V., Mathiowetz, A. M., Mitchell, J. M., Piotrowski, D. W., Price, D. A., Stanton, R. V., Suen, J. Y., Withka, J. M., Griffith, D. A., and Fairlie, D. P. (2015) Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. *J. Med. Chem.* 58, 4080–4085.

(43) Dal Maso, E., Zhu, Y., Pham, V., Reynolds, C. A., Deganutti, G., Hick, C. A., Yang, D., Christopoulos, A., Hay, D. L., Wang, M. W., Sexton, P. M., Furness, S. G. B., and Wootten, D. (2018) Extracellular loops 2 and 3 of the calcitonin receptor selectively modify agonist binding and efficacy. *Biochem. Pharmacol.* 150, 214–244.

(44) Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., Simms, J., Sridhar, R., Furness, S. G., Liu, M., Thompson, P. E., Miller, L. J., Christopoulos, A., and Sexton, P. M. (2016) The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism. *Cell* 165, 1632–1643.

(45) Gkountelias, K., Tselios, T., Venihaki, M., Deraos, G., Lazaridis, I., Rassouli, O., Gravanis, A., and Liapakis, G. (2009) Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. *Mol. Pharmacol.* 75, 793–800.

(46) Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K., Dore, A. S., Jazayeri, A., Cooke, R. M., Weir, M., and Marshall, F. H. (2013) Structure of class B GPCR corticotropin-releasing factor receptor 1. *Nature* 499, 438–443.